Literature DB >> 23770787

Role of combined procalcitonin and lipopolysaccharide-binding protein as prognostic markers of mortality in patients with ventilator-associated pneumonia.

Cleopas M Rumende1, Dinajani Mahdi.   

Abstract

AIM: to investigate the role of combined Lipopolysaccharide-Binding Protein (LBP) and Procalcitonin (PCT) ) as prognostic marker of mortality in patients with Ventilator-Associated Pneumonia (VAP).
METHODS: this prospective cohort study was held in ICU/HCU of Cipto Mangunkusumo hospital between 2006 to 2007 by taking the subjects consecutively. Thirty five patients with VAP were studied. For analysing the data, chi-square or its alternative Fisher exact test were used. Based on a previous study for evaluation, we used cut off pants of 5 ng/ml and 0.5 ng/ml for PCT and 30 µg/ml and 25 µg/ml for LBP after three-day and seven-day treatment respectively. Receiver operating curve was made to determine the sensitivity and specificity of PCT and LBP as infection markers.
RESULTS: 35 patients participated in this study. After three days of therapy, if the level of PCT >5 ng/mL and LBP >30 µg/mL the prognosis would be bad (p<0.05) with a sensitivity of 88.5%, specificity of 53.2% and AUC value 0.69. Poor prognosis was also found if after seven day therapy PCT level was >0.5 ng/mL and LBP level >25 µg/mL (p<0.05) with sensitivity of 96.3%, specificity of 66.7% and AUC value 0.81.
CONCLUSION: examination of combined PCT and LBP can be taken as a good prognostic markers to predict mortality in patients with VAP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770787

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  1 in total

1.  Effect of Vitamin D Supplementation on Procalcitonin as Prognostic Biomarker in Patients with Ventilator Associated Pneumonia Complicated with Vitamin D Deficiency.

Authors:  Amir Ebrahim Miroliaee; Jamshid Salamzadeh; Shervin Shokouhi; Alireza Fatemi; Seyed Hossein Ardehali; Mohammad Reza Hajiesmaeili; Zahra Sahraei
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.